These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
187 related articles for article (PubMed ID: 1491396)
1. Effect of calcitonin or the anabolic steroid Decadurabolin on serum beta 2 microglobulin in osteoporotic postmenopausal women. Cantatore FP; Loperfido MC; Mancini L; Carrozzo M J Rheumatol; 1992 Nov; 19(11):1753-5. PubMed ID: 1491396 [TBL] [Abstract][Full Text] [Related]
2. Effects of nandrolone decanoate and antiresorptive therapy on vertebral density in osteoporotic postmenopausal women. Need AG; Horowitz M; Bridges A; Morris HA; Nordin BE Arch Intern Med; 1989 Jan; 149(1):57-60. PubMed ID: 2912415 [TBL] [Abstract][Full Text] [Related]
3. Assessment of bone turnover in postmenopausal osteoporosis by measurement of serum bone Gla-protein. Delmas PD; Wahner HW; Mann KG; Riggs BL J Lab Clin Med; 1983 Oct; 102(4):470-6. PubMed ID: 6604769 [TBL] [Abstract][Full Text] [Related]
4. Effects of nandrolone therapy on forearm bone mineral content in osteoporosis. Need AG; Horowitz M; Morris HA; Walker CJ; Nordin BE Clin Orthop Relat Res; 1987 Dec; (225):273-8. PubMed ID: 3677513 [TBL] [Abstract][Full Text] [Related]
5. Relationship between serum beta 2-microglobulin, bone histology, and dialysis membranes in uraemic patients. Ferreira A; Ureña P; Ang KS; Simon P; Morieux C; Souberbielle JC; de Vernejoul MC; Drüeke TB Nephrol Dial Transplant; 1995; 10(9):1701-7. PubMed ID: 8559492 [TBL] [Abstract][Full Text] [Related]
6. An evaluation of several biochemical markers for bone formation and resorption in a protocol utilizing cyclical parathyroid hormone and calcitonin therapy for osteoporosis. Hodsman AB; Fraher LJ; Ostbye T; Adachi JD; Steer BM J Clin Invest; 1993 Mar; 91(3):1138-48. PubMed ID: 8450043 [TBL] [Abstract][Full Text] [Related]
7. Influence of the selective oestrogen receptor modulator (raloxifene hydrochloride) on IL-6, TNF-alpha, TGF-beta1 and bone turnover markers in the treatment of postmenopausal osteoporosis. Ozmen B; Kirmaz C; Aydin K; Kafesciler SO; Guclu F; Hekimsoy Z Eur Cytokine Netw; 2007 Sep; 18(3):148-53. PubMed ID: 17823083 [TBL] [Abstract][Full Text] [Related]
8. Anabolic steroids in corticosteroid-induced osteoporosis. Adami S; Rossini M Wien Med Wochenschr; 1993; 143(14-15):395-7. PubMed ID: 8256456 [TBL] [Abstract][Full Text] [Related]
9. [Clinical efficacy of treatment with salmon calcitonin, administered intranasally for 1 year, in stabilized postmenopausal osteoporosis]. Agnusdei D; Gonnelli S; Camporeale A; Batignani T; Nardi P; Ianes A; Gennari C Minerva Endocrinol; 1989; 14(3):169-76. PubMed ID: 2695815 [TBL] [Abstract][Full Text] [Related]
10. Treatment of postmenopausal osteoporosis: is the anabolic steroid nandrolone decanoate a candidate? Johansen JS; Hassager C; Pødenphant J; Riis BJ; Hartwell D; Thomsen K; Christiansen C Bone Miner; 1989 Apr; 6(1):77-86. PubMed ID: 2665884 [TBL] [Abstract][Full Text] [Related]
11. [Behavior of urinary excretion of cyclic AMP in post-menopausal osteoporosis during therapy with salmon calcitonin]. Nuti R; Galli M; Righi GA; Turchetti V; Campagna MS; Franci B Minerva Med; 1982 May; 73(19):1283-9. PubMed ID: 6281691 [TBL] [Abstract][Full Text] [Related]
12. [Current research in therapy of postmenopausal osteoporosis (author's transl)]. Laroche C; Detilleux M; Sereni D Sem Hop; 1979 Feb 18-25; 55(7-8):325-9. PubMed ID: 220722 [TBL] [Abstract][Full Text] [Related]
13. Evaluation of bone turnover and osteoclastic cytokines in early rheumatoid arthritis treated with alendronate. Cantatore FP; Acquista CA; Pipitone V J Rheumatol; 1999 Nov; 26(11):2318-23. PubMed ID: 10555884 [TBL] [Abstract][Full Text] [Related]
14. Alendronate stimulation of nocturnal parathyroid hormone secretion: a mechanism to explain the continued improvement in bone mineral density accompanying alendronate therapy. Greenspan SL; Holland S; Maitland-Ramsey L; Poku M; Freeman A; Yuan W; Kher U; Gertz B Proc Assoc Am Physicians; 1996 May; 108(3):230-8. PubMed ID: 8774056 [TBL] [Abstract][Full Text] [Related]
15. Anabolic steroids in postmenopausal osteoporosis. Need AG; Durbridge TC; Nordin BE Wien Med Wochenschr; 1993; 143(14-15):392-5. PubMed ID: 8256455 [TBL] [Abstract][Full Text] [Related]
16. Comparison of zinc excretion and biochemical markers of bone remodelling in the assessment of the effects of alendronate and calcitonin on bone in postmenopausal osteoporosis. Gur A; Colpan L; Cevik R; Nas K; Jale Sarac A Clin Biochem; 2005 Jan; 38(1):66-72. PubMed ID: 15607319 [TBL] [Abstract][Full Text] [Related]
17. Effects of nandrolone decanoate on plasma calcitonin, parathormone and vitamin D, in elderly women. Cantatore FP; D'Amore M; Carrozzo M; Pipitone V Panminerva Med; 1987; 29(3):203-5. PubMed ID: 3696754 [No Abstract] [Full Text] [Related]
18. Changes of bone markers during long-term intravenous calcitriol therapy in maintenance dialysis patients. Lee SH; Huang TS; Hsieh SJ Miner Electrolyte Metab; 1996; 22(4):219-23. PubMed ID: 8807625 [TBL] [Abstract][Full Text] [Related]
19. Metabolic and bone effects after administration of ipriflavone and salmon calcitonin in postmenopausal osteoporosis. Cecchettin M; Bellometti S; Cremonesi G; Solimeno LP; Torri G Biomed Pharmacother; 1995; 49(10):465-8. PubMed ID: 8746073 [TBL] [Abstract][Full Text] [Related]
20. The carboxy-terminal pyridinoline cross-linked telopeptide of type I collagen in serum as a marker of bone resorption: the effect of nandrolone decanoate and hormone replacement therapy. Hassager C; Jensen LT; Pødenphant J; Thomsen K; Christiansen C Calcif Tissue Int; 1994 Jan; 54(1):30-3. PubMed ID: 8118750 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]